Patents Assigned to Coulter Pharmaceutical, Inc.
-
Patent number: 6565827Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.Type: GrantFiled: August 7, 2001Date of Patent: May 20, 2003Assignees: Coulter Pharmaceutical, Inc., The Regents of the University of MichiganInventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
-
Patent number: 6338835Abstract: A method of ameliorating degradation radiolabeled peptides, especially radiolabeled proteins such as antibodies, by including povidone, also widely known as polyvinylpyrrolidone or PVP, as a radioprotectant in a composition containing a radiolabeled peptide is described. A radioprotectant composition and a stable peptide-radioisotope composition having povidone are also described. Ascorbic acid or other secondary stabilizers may also be added to the compositions to further enhance radioprotection.Type: GrantFiled: December 2, 1999Date of Patent: January 15, 2002Assignee: Coulter Pharmaceutical, Inc.Inventors: Dan Shochat, Albert S. K. Chan, Michael J. Buckley, David Colcher
-
Patent number: 6287537Abstract: Methods for the treatment of lymphoma by adminstration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.Type: GrantFiled: May 29, 1998Date of Patent: September 11, 2001Assignees: The Regents of the University of Michigan, Coulter Pharmaceutical, Inc.Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
-
Patent number: 6090365Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.Type: GrantFiled: November 18, 1997Date of Patent: July 18, 2000Assignees: Coulter Pharmaceutical, Inc., Regents of the University of MichiganInventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
-
Patent number: 6015542Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy also described is a composition useful in the treatment of lymphoma.Type: GrantFiled: September 10, 1996Date of Patent: January 18, 2000Assignees: Coulter Pharmaceutical, Inc., The Regents of the University of MichiganInventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
-
Patent number: 5961955Abstract: A method of ameliorating degradation of radiolabeled peptides, especially radiolabeled proteins such as antibodies, by including povidone, also widely known as polyvinylpyrrolidone or PVP, as a radioprotectant in a composition containing a radiolabeled peptide is described. A radioprotectant composition and a stable peptide-radioisotope composition having povidone are also described. Ascorbic acid or other secondary stabilizers may also be added to the compositions to further enhance radioprotection.Type: GrantFiled: August 21, 1997Date of Patent: October 5, 1999Assignee: Coulter Pharmaceutical, Inc.Inventors: Dan Shochat, Albert S. K. Chan, Michael J. Buckley, David Colcher
-
Patent number: 5843398Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.Type: GrantFiled: April 26, 1996Date of Patent: December 1, 1998Assignees: Coulter Pharmaceutical, Inc., Regents of the University of MichiganInventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
-
Patent number: 5595721Abstract: Methods for the treatment of lymphoma by adminstration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.Type: GrantFiled: September 16, 1993Date of Patent: January 21, 1997Assignee: Coulter Pharmaceutical, Inc.Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
